The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients

被引:10
作者
Hasegawa, Masahiro [1 ]
Tone, Shine [1 ]
Wada, Hideo [2 ,3 ]
Naito, Yohei [1 ]
Matsumoto, Takeshi [4 ]
Yamashita, Yoshiki [5 ]
Shimaoka, Motomu [6 ]
Sudo, Akihiro [1 ]
机构
[1] Mie Univ, Dept Orthopaed Surg, Grad Sch Med, Tsu, Mie, Japan
[2] Mie Prefectural Gen Med Ctr, Associated Dept Mie Grad Sch Med, 5450-132 Ohaza Hinaga, Yokaichi, Mie 5108561, Japan
[3] Mie Prefectural Gen Med Ctr, Dept Gen Med, 5450-132 Ohaza Hinaga, Yokaichi, Mie 5108561, Japan
[4] Mie Univ Hosp, Div Blood Transfus & Cell Therapy, Tsu, Mie, Japan
[5] Mie Univ, Dept Hematol & Oncol, Grad Sch Med, Tsu, Mie, Japan
[6] Mie Univ, Dept Mol Pathobiol & Cell Adhes Biol, Grad Sch Med, Tsu, Mie, Japan
关键词
sTF; FIXa; APTT; CWA; edoxaban; orthopedic surgery; PARTIAL THROMBOPLASTIN TIME; DEEP-VEIN THROMBOSIS; WAVE-FORM ANALYSIS; ANTI-XA ACTIVITY; VENOUS THROMBOEMBOLISM; COAGULATION ASSAYS; APTT; THROMBOPROPHYLAXIS; METAANALYSIS; RIVAROXABAN;
D O I
10.1177/10760296211012094
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We analyzed the utility for a clot waveform analysis (CWA) of small tissue factor induced FIX activation (sTF/FIXa) assay in patients with major orthopedic surgery (including total hip arthroplasty [THA] and total knee arthroplasty [TKA]) receiving edoxaban for the prevention of venous thromboembolism (VTE). The sTF/FIXa assay using recombinant human TF in platelet-rich plasma (PRP) and platelet-poor plasma (PPP) was performed using a CWA in the above patients to monitor the efficacy of edoxaban administration. Of 147 patients (109 THA and 38 TKA), 21 exhibited deep vein thrombosis (DVT), and 15 had massive bleeding. Increased peak heights of the CWA-sTF/FIX were observed in almost patients after surgery and prolonged peak heights of the CWA-sTF/FIX were observed in almost patients treated with edoxaban. The peak heights and times of the CWA-sTF/FIX were significantly higher and shorter, respectively, in PRP than in PPP. There were no significant differences in parameters of the CWA-sTF/FIXa between the patients with and without DVT or between those with and without massive bleeding. The peak time of CWA-sTF/FIXa were significantly longer in TKA patients than in THA patients on day 1 after surgery. The second derivative peak height of the CWA-sTF/FIXa was significantly lower in TKA patients than in THA patients on day 4. The CWA-sTF/FIX reflected hemostatic abnormalities after surgery and the administration of edoxaban, and the results were better in PRP than PPP. Further studies separately analyzing the THA and TKA subgroups should be conducted.
引用
收藏
页数:8
相关论文
共 27 条
[1]   Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis [J].
Feng, Weili ;
Wu, Kezhou ;
Liu, Zhaoyong ;
Kong, Gengbin ;
Deng, Zhihua ;
Chen, Shubiao ;
Wu, Yudan ;
Chen, Mengmeng ;
Liu, Shuo ;
Wang, Hu .
THROMBOSIS RESEARCH, 2015, 136 (06) :1133-1144
[2]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Heit, JA ;
Clagett, GP ;
Pineo, GF ;
Colwell, CW ;
Anderson, FA ;
Wheeler, HB .
CHEST, 2001, 119 (01) :132S-175S
[3]   Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? [J].
Gosselin, Robert C. ;
Francart, Suzanne J. ;
Hawes, Emily M. ;
Moll, Stephan ;
Dager, William E. ;
Adcock, Dorothy M. .
ANNALS OF PHARMACOTHERAPY, 2015, 49 (07) :777-783
[4]   Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays [J].
Gouin-Thibault, Isabelle ;
Flaujac, Claire ;
Delavenne, Xavier ;
Quenet, Sara ;
Horellou, Marie-Helene ;
Laporte, Silvy ;
Siguret, Virginie ;
Lecompte, Thomas .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) :240-248
[5]   Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform [J].
Hasegawa, M. ;
Wada, H. ;
Tone, S. ;
Yamaguchi, T. ;
Wakabayashi, H. ;
Ikejiri, M. ;
Watanabe, M. ;
Fujimoto, N. ;
Matsumoto, T. ;
Ohishi, K. ;
Yamashita, Y. ;
Katayama, N. ;
Sudo, A. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) :49-55
[6]   The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery [J].
Hasegawa, Masahiro ;
Wada, Hideo ;
Wakabayashi, Hiroki ;
Yoshida, Kakunoshin ;
Miyamoto, Noriki ;
Asanuma, Kunihiro ;
Matsumoto, Takeshi ;
Ohishi, Kohshi ;
Shimokariya, Yuji ;
Yamada, Norikazu ;
Uchida, Atsumasa ;
Sudo, Akihiro .
CLINICA CHIMICA ACTA, 2013, 425 :109-113
[7]   Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009) [J].
Huang, W. ;
Goldberg, R. J. ;
Cohen, A. T. ;
Anderson, F. A. ;
Kiefe, C. I. ;
Gore, J. M. ;
Spencer, F. A. .
THROMBOSIS RESEARCH, 2015, 135 (06) :1100-1106
[8]   Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux [J].
Ikejiri, Makoto ;
Wada, Hideo ;
Yamaguchi, Toshio ;
Miyazaki, Shinichi ;
Hasegawa, Masahiro ;
Wakabayashi, Hiroki ;
Asanuma, Kunihiro ;
Sakaguchi, Akane ;
Matsumoto, Takeshi ;
Ohishi, Kohshi ;
Fujimoto, Naoki ;
Yamada, Norikazu ;
Ito, Masaaki ;
Katayama, Naoyuki ;
Sudo, Akihiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (05) :554-559
[9]   Clinical Application of Thromboelastography/Thromboelastometry (TEG/TEM) in the Neonatal Population: A Narrative Review [J].
Konstantinidi, Aikaterini ;
Sokou, Rozeta ;
Parastatidou, Stavroula ;
Lampropoulou, Katerina ;
Katsaras, George ;
Boutsikou, Theodora ;
Gounaris, Antonios K. ;
Tsantes, Argyrios E. ;
Iacovidou, Nicoletta .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (05) :449-457
[10]   Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab: comment [J].
Matsumoto, T. ;
Wada, H. ;
Toyoda, H. ;
Hirayama, M. ;
Yamashita, Y. ;
Katayama, N. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (08) :1665-1666